NCT06477302 Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer
| NCT ID | NCT06477302 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Instituto Nacional de Cancerologia de Mexico |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 281 participants |
| Start Date | 2023-06-23 |
| Primary Completion | 2026-06-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 281 participants in total. It began in 2023-06-23 with a primary completion date of 2026-06-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this non experimental, transversal instrument study is to Construct and determine the reliability and validity of the Scale of Therapeutic Adherence for Respiratory Rehabilitation in Lung Cancer in Mexican patients with a lung cancer diagnosis. The main question it aims to answer is: What is the reliability and validity of the Scale of Therapeutic Adherence for Respiratory Rehabilitation in Lung Cancer of the patients with this diagnosis that are currently undergoing an assessment or follow up program of Respiratory Rehabilitation? The Scale of Therapeutic Adherence for Respiratory Rehabilitation in Lung Cancer (STA-RR-LC) will be psychometrically valid and reliable for the evaluation of therapeutic adherence on patients with lung cancer that are undergoing an assessment or follow up of Respiratory Rehabilitation.Participants will be asked to fill out an Identification card and fill out the fifty-six items presented on the STA-RR-LC.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with lung cancer (SCLC and NSCLC). * Over 18 years of age. * Voluntary participation by understanding and accepting the informed consent letter. * Patients undergoing Respiratory Rehabilitation treatment with one month assessment and follow-up. * Patients in active medical treatment. * Any clinical stage. * Karnofsky Index ≥ 70. Exclusion Criteria: * Severe hearing or visual problems that prevent them from understanding the instructions and answering the instruments (this will be identified as reported in the clinical record file). * Severe psychiatric conditions (schizophrenia or psychotic disorders) and/or addiction to any psychoactive substance (this will be identified as reported in the INCanet file). * Attentional or memory problems that prevent them from understanding the instructions and answering the instruments (this will be identified as reported in the INCanet file).
Contact & Investigator
Oscar G Arrieta, MD
PRINCIPAL INVESTIGATOR
Instituto Nacional de Cancerologia (INCan) Mexico
Frequently Asked Questions
Who can join the NCT06477302 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06477302 currently recruiting?
Yes, NCT06477302 is actively recruiting participants. Contact the research team at ogar@unam.mx for enrollment information.
Where is the NCT06477302 trial being conducted?
This trial is being conducted at Mexico City, Mexico.
Who is sponsoring the NCT06477302 clinical trial?
NCT06477302 is sponsored by Instituto Nacional de Cancerologia de Mexico. The principal investigator is Oscar G Arrieta, MD at Instituto Nacional de Cancerologia (INCan) Mexico. The trial plans to enroll 281 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.